Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2025)

Xeris Biopharma Holdings' Retained Earnings history spans 6 years, with the latest figure at -$671.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 2685128.0% year-over-year to -$671.3 million, compared with a TTM value of -$671.3 million through Dec 2025, down 2685128.0%, and an annual FY2025 reading of -$671.3 million, down 2685128.0% over the prior year.
  • Retained Earnings for Q4 2025 was -$671.3 million at Xeris Biopharma Holdings, up from -$682.4 million in the prior quarter.
  • The five-year high for Retained Earnings was -$23000.0 in Q4 2022, with the low at -$683.0 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$343.4 million, with a median of -$506.9 million recorded in 2022.
  • Year-over-year, Retained Earnings skyrocketed 100.0% in 2024 and then plummeted 2685128.0% in 2025.
  • Tracing XERS's Retained Earnings over 5 years: stood at -$31000.0 in 2021, then grew by 25.81% to -$23000.0 in 2022, then crashed by 2682617.39% to -$617.0 million in 2023, then surged by 100.0% to -$25000.0 in 2024, then plummeted by 2685128.0% to -$671.3 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Retained Earnings are -$671.3 million (Q4 2025), -$682.4 million (Q3 2025), and -$683.0 million (Q2 2025).